The European Business Association Health Care Committee (The Association’s Committee) repeatedly brought the attention of the state authorities to the need of avoiding patients’ treatment interruption as a result of the New Essential Drugs List (EML) introduction starting from 1 July 2017. Now we are pleased to note that the problem was solved by postponing some provisions.
The issue was to ensure this year procurement of those drugs, which were not included into the new EML but appeared indispensable for medical institutions to ensure no interruption of the therapy that has been already applied for a number of patient categories. The loss of validity of the List approved by the CMU Resolution No.1071 from 1 July 2017 could lead to unexpected problems on the way to continuing procurements of necessary drugs by medical institutions and, accordingly, have undesirable consequences for patients.
On 25 July 2017 the CMU web we were pleased to see the publication of the adopted amendments to the new EML, which postponed the introduction of new requirements for drugs procurement for budget funds by 1 September 2017. Thus, medical institutions have been granted a transitional period in order to complete the drugs procurements in accordance with the requirements that existed before 1 July 2017.
In addition, the new requirement for the procurement of drugs, not included into the National List, only after the full satisfaction of the requirements for those drugs included into the National List has been postponed till 1 January, 2018.
The Association Committee welcomes the amendments adoption, expects their fast publication in official sources and hopes that the established transition period will enable medical institutions to complete the drugs procurement procedures that have already been started.
Further on and, prior to the beginning of the 2018, we expect that in conjunction with MOH of Ukraine, Expert Committee on new EML and other concerned parties we will be able to achieve better understanding as regards all procedures related to the decisions on further inclusion of new medical drugs into the new EML.